Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
128
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.

Translational lung cancer research·2026
Same author

Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer.

Cancer·2026
Same author

ASO Author Reflections: Peritoneal Disease Control after Complete Cytoreductive Surgery in Patients with Colorectal Cancer and Extraperitoneal Metastases.

Annals of surgical oncology·2026
Same author

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non-small cell lung cancer.

Translational lung cancer research·2026
Same author

ASO Visual Abstract: Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis.

Annals of surgical oncology·2026
Same author

Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis.

Annals of surgical oncology·2026
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K

Pancreatic Cancer Immunotherapy: A Team-Based Approach.

Krushangi Patel1, Percy Lee2, Julius Weng2

  • 1City of Hope Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center Long Beach, Long Beach, CA, USA. KruPatel@coh.org.

Cancer Treatment and Research
|August 23, 2025
PubMed
Summary
This summary is machine-generated.

Immunotherapy shows promise in cancer treatment but faces challenges in pancreatic cancer. Overcoming the tumor microenvironment is key to developing effective immunotherapies for pancreatic cancer patients.

Keywords:
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)Immune checkpoint blockade (ICB)Overall response rate (ORR)Overall survival (OS)Pancreatic ductal adenocarcinoma (PDAC)Programmed cell death protein 1 (PD1)Progression-free survival (PFS)Tumor microenvironment (TME)Tumor-infiltrating lymphocyte therapy (TILs)

More Related Videos

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.5K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.4K

Related Experiment Videos

Last Updated: Sep 10, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.5K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.4K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immunotherapy offers effective cancer treatment with manageable toxicity.
  • Pancreatic cancer has shown limited response to current immunotherapeutic strategies.
  • The tumor microenvironment presents a significant barrier to immunotherapy efficacy in pancreatic cancer.

Purpose of the Study:

  • To explore the challenges limiting immunotherapy effectiveness in pancreatic cancer.
  • To understand the role of the tumor microenvironment in pancreatic cancer progression and treatment resistance.
  • To identify strategies for optimizing immunotherapeutic approaches in pancreatic cancer.

Main Methods:

  • Review of current literature on cancer immunotherapy.
  • Analysis of the pancreatic tumor microenvironment's impact on immune responses.
  • Exploration of therapeutic development strategies for pancreatic cancer.

Main Results:

  • Immunotherapy efficacy is often limited in pancreatic cancer.
  • The pancreatic tumor microenvironment is a major obstacle to successful immunotherapy.
  • A comprehensive, team-based approach is needed to understand and overcome these challenges.

Conclusions:

  • Addressing the hostile tumor microenvironment is crucial for advancing pancreatic cancer immunotherapy.
  • Optimizing treatment strategies requires a deep understanding of pancreatic cancer biology and its microenvironment.
  • Developing combination therapies may lead to long-standing efficacy for pancreatic cancer patients.